Quality of life in multiple sclerosis: influence of interferon-β1a (Avonex®) treatment
Abstract
Background Numerous data argue for initiating treatment with interferon-beta (IFN-beta) at an early stage in multiple sderosis (MS). The consequences of its use may negatively influence the MS patient's quality of life (QoL). Objective To evaluate the QoL of MS patients before and after a one-year period of treatment with IFN-beta1a (Avonex). Patients and methods QoL was assessed using the SF-36 in 121 relapsing-remitting MS patients. We compared QoL before and after treatment and with data from a normal population. We also studied the possible influence of disease progression on the SF-36 scores. Results One hundred six patients completed the study (87%). Compared to a normal population, patients were, at baseline, worse off for all QoL scales, varying from a minimum decrease of 0.73 SD in mental health, to a maximum decrease of 1.55 SD in general health. After treatment, we found no significant changes in any of the QoL scores, except for physical function, where we noted a slight but significant decrease (p = 0.03). Furthermore, there was no significant change either in the physical component summary (PCS) or mental component summary (MCS). The 'reported health transition' item was significantly improved compared to baseline (p = 0.001). At indusion, significant correlations were found between EDSS scores and scores of physical function (p Conclusion The QoL, assessed by the SF-36 scale, is correlated with disability in MS. IFN-beta1a treatment (Avonex) has no negative eff…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Many disease-modifying drug regimens appear to produce modest or no improvements in HRQOL or even negative changes.
“many disease-modifying drug regimens appear to produce modest or no improvements in HRQOL7,11–14 or even negative changes.15”
From MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial (2010) · cites this paper as [12]
HRQOL has gained increasing status as a metric of treatment effectiveness.
“although HRQOL has gained increasing status as a metric of treatment effectiveness.11–14,20”
From MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial (2010) · cites this paper as [12]
Disease-modifying treatments do not necessarily have beneficial impact upon HRQOL or coping responses.
“Disease-modifying treatments do not necessarily have beneficial impact upon HRQOL or coping responses.7,11–13”
From MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial (2010) · cites this paper as [12]
Cites
A health-related quality of life measure for multiple sclerosis
Vickrey, B. G., Hays, R. D., Harooni, R., Myers, L. W., & Ellison, G. W. (1995) · Quality of Life Research · doi:10.1007/bf02260859 · Cited by 1,132 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Benedict, R. H. B., Wahlig, E., Bakshi, R., Fishman, I., Munschauer, F., Zivadinov, R., & Weinstock-Guttman, B. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.12.009 · Cited by 528 · see citing works
MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial
Grossman, P., Kappos, L., Gensicke, H., D'Souza, M., Mohr, D. C., Penner, I. K., & Steiner, C. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f4d80d · Cited by 419 · see citing works
Illness perception and health-related quality of life in multiple sclerosis.
Spain, L. A., Tubridy, N., Kilpatrick, T. J., Adams, S. J., & Holmes, A. C. N. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00895.x · Cited by 97 · see citing works
Zivadinov, R., Zorzon, M., Tommasi, M. A., Nasuelli, D., Bernardi, M., Monti-Bragadin, L., & Cazzato, G. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(03)00225-9 · Cited by 81 · see citing works
- Authors
- Vermersch, P., de Seze, J., Delisse, B., Lemaire, S., & Stojkovic, T.
- Affiliations
- Hôpital Roger Salengro (FR)
- Department of Neurology, Hôpital R. Salengro, Lille 59037, France
- Centre Hospitalier de Lens (FR)
- Corresponding author
- Vermersch, P
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2002-10
- Volume
- 8
- Issue
- 5
- Pages
- 377-381
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2157204060
- Cited by
- 74
- References
- 1
- Citations by year
- 2022: 1 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 4 · 2016: 3 · 2015: 2 · 2014: 5 · 2013: 4 · 2012: 3
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Multiple Sclerosis Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Keywords
- multiple sclerosis, quality of life, interferon beta-1a, Avonex, relapsing-remitting multiple sclerosis, SF-36, disability progression, Expanded Disability Status Scale, physical function, social function, early treatment
- MeSH terms
- Interferon beta-1a, Adjuvants, Immunologic, Adult, Disability Evaluation, Female, Humans, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Interferon-beta, Disease Progression, Multiple Sclerosis, Relapsing-Remitting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
